NCT06147388 (RECER) is a clinical trial of Colposcopy in Cervix Uteri SIL, sponsored by General University Hospital, Prague.

Who is sponsoring NCT06147388?

NCT06147388 is sponsored by General University Hospital, Prague.

What drugs are being tested in NCT06147388?

Interventions in NCT06147388: Colposcopy.

What condition does NCT06147388 study?

NCT06147388 studies Cervix Uteri SIL, HPV, CIN2, CIN3.

Is NCT06147388 still recruiting?

NCT06147388 is currently recruiting now. Last updated 25 February 2026.

Last reviewed 2026-02-25 · How we verify

NCT06147388: RECER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Regression of Cervical Precancerous Lesions and Associated Risk Factors

Recruiting now Last updated 25 February 2026

What this trial tests

trial testing Colposcopy in Cervix Uteri SIL in 300 participants. Currently enrolling.

Timeline

1 September 2022

Primary endpoint
1 July 2026

1 July 2027

Quick facts

Lead sponsor	General University Hospital, Prague
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	1 September 2022
Primary completion	1 July 2026
Estimated completion	1 July 2027
Sites	1 location across Czechia

Drugs / interventions tested

Colposcopy

Conditions studied

Cervix Uteri SIL — all drugs for Cervix Uteri SIL →
HPV — all drugs for HPV →
CIN2 — all drugs for CIN2 →
CIN3 — all drugs for CIN3 →

Sponsor

General University Hospital, Prague

Who can join

Adults 18 to 40, female only, with Cervix Uteri SIL or HPV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess the extent of histopathological regression of severe cervical precancerous lesions (CIN 2 and CIN 3); evaluate the proportion of patients who experience the normalization of HPV test and cytology finding among those who were treated conservatively and those who underwent conization; and identify predictive parameters associated with regression. Based on this analysis, a model will be proposed to predict the likelihood of lesion regression.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Regression of high-grade squamous intraepithelial cervical lesions and associated risk factors (RECER).
Dostalek L, Brynda D, Marek R, Hederlingova J, et al · · 2025 · PMID 40215795 · DOI 10.1016/j.ijgc.2025.101768

Verify or expand the search:

Other trials of Colposcopy

Trials testing the same drug.

NCT07211204 — Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population · NA · withdrawn
NCT07281430 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) · NA · recruiting
NCT06611553 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) · NA · active not recruiting
NCT06611540 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) · NA · active not recruiting
NCT06498661 — Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · NA · recruiting

Other General University Hospital, Prague trials

Trials by the same sponsor.

NCT07493928 — HPV After chemoRadioTherapy · recruiting
NCT07495410 — Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT · NA · enrolling by invitation
NCT06942533 — Effect of Visual Feedback From the SpiroGym Mobile Application · NA · recruiting
NCT06789978 — Rapid Prehospital ACcess to ECPR in Prague · NA · recruiting
NCT06585332 — Handgrip and Respiratory Dysfunction in HD Patients. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06147388 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by General University Hospital, Prague
Last refreshed: 25 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06147388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing